The two platforms involved in the study were the FHX regimen and a cisplatin radiation approach with accelerated radiation. Siltuximab was also used in the study as induction chemotherapy alongside carboplatin and paclitaxel.
Ezra Cohen, MD, professor of medicine, UC San Diego Moores Cancer Center, discusses a recent study looking at integrating siltuximab into two different chemotherapy radiation platforms. The two platforms involved in the study were the FHX regimen and a cisplatin radiation approach with accelerated radiation. Siltuximab was also used in the study as induction chemotherapy alongside carboplatin and paclitaxel. Cohen says patients were initially given the triplet, and then randomized to either the FHX regimen and a cisplatin radiation approach.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More